Skip to main content
OpenTrials
Completed

NCT Number: NCT07587164

C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia

This is an operational research in household/close contacts of confirmed TB patients to evaluate the effectiveness of C-TST compared to IGRA test in identifying latent TB cases using parameters of effectiveness and safety.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

RSUP Persahabatan (Persahabatan General Hospital)

Jakarta, Jakarta Timur (East Jakarta), 13220, Indonesia

About this study

The study is designed as an operational research. After informed consent and screening by evaluation of medical history followed by thorough physical examination and vital signs test (body temperature, blood pressure, pulse rate, and respiration rate) and urine pregnancy test for women of childbearing potential, blood collection will be done in 300 eligible subjects for IGRA test, followed by C-TST skin test. Measure the body temperature of all subjects 30 min after the skin test. Test results will be observed with skin reaction at the injection site 48~72 h after the skin test. Test results along with presence of adverse events until 7 days follow-up will be recorded. If there are discrepancies in the test result, a T-SPOT test will be conducted after the skin test.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years - 65 years old
  • Being a close contact or household contact of a TB patient
  • Subject and/or legally acceptable representatives of the subject are willing to participate in the research by providing informed consent.
  • On the day of enrollment, the axillary body temperature was normal (<37.3 °C)

Exclusion criteria

  • Pregnant or lactating women
  • Individuals with active TB or those presenting symptoms suggestive of TB.
  • Patients with acute infectious diseases (such as measles, whooping cough, influenza, pneumonia, etc), acute conjunctivitis, acute otitis media, extensive skin diseases, and allergic constitution.
  • Have a history of TB disease
  • Received a TST within the last 6 months
  • Presence of skin conditions that might interfere with the interpretation after C-TST administration, such as tattoo and abnormal skin condition.
  • Currently participating in a clinical trial for medication.
  • Condition where researchers believe that there are any situations that may affect the evaluation of the trial.

Treatment and study plan

Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST)

Drug

The study was a prospective, open-label, non-randomized study. All subjects underwent IGRA testing (QFT), followed by C-TST administration. T-SPOT.TB tests were performed only in cases of any discrepancies in the results between C-TST and QFT and were used as part of a composite reference standard. Subjects then underwent blood collection (6 mL venous blood) using lithium-heparin tube for IGRA Quantiferon® testing, followed by administration of 0.1 mL 5 U C-TST intradermally on the palm side of the forearm using Mantoux method on Day 1. Blood collection and administration of C-TST were performed by an authorized site nurse from each site.

Primary outcomes

  1. Acceptance rate between C-TST and IGRA test in identifying latent TB infection in household and close contact populations.

    Time frame: 7 days after the skin test

    The primary outcome is the concordance between C-TST and QuantiFERON-TB (QFT) results. All subjects underwent QFT testing followed by 0.1 mL 5 U C-TST administered intradermally on the forearm using the Mantoux method. In cases of discrepant results between C-TST and QFT, T-SPOT.TB testing was performed as part of a composite reference standard. Concordance will be calculated based on agreement rates between the tests.

Secondary outcomes

  1. Safety endpoints: Incidence of all AEs within 7 days after skin test injection.

    Time frame: within 7 days after the skin test

    • Overall incidence of AEs;
    • Immediate AEs within 30 minutes after skin test injection;
    • Incidence of AEs related to the investigational product;
    • Incidence of AEs ≥ grade 3;
    • Incidence of AEs ≥ grade 3 related to the investigational product;
    • Incidence of AEs leading to withdrawal;
    • Incidence of AEs related to the investigational product leading to withdrawal; Incidence of all serious adverse events (SAEs) and incidence of SAEs related to the investigational product within 7 days after the skin test.
  2. Incremental Cost Effectiveness Ratio

    Time frame: Day 7 after skin test

    On the third visit, subjects will be asked to fill out an acceptability questionnaire. In additional to assess cost-effectiveness, investigator will use primary data obtained from health workers (doctors, nurses, and laboratory workers) as well as cost summary used in laboratories. Other data will be obtained from secondary data and model assumptions.

Sponsors and collaborators

Lead sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Industry

Collaborators

  • Respiratory Programmatic Implementation and Research Institute (RPRI)

Registry information

Official study title

Operational Research of Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST) for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Populations Aged 18 Years to 65 Years Old in Indonesia

Acronym: C-TST

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 14, 2026
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.